GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HUTCHMED (China) Ltd (NAS:HCM) » Definitions » ROE % Adjusted to Book Value

HUTCHMED (China) (HUTCHMED (China)) ROE % Adjusted to Book Value : -4.24% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is HUTCHMED (China) ROE % Adjusted to Book Value?

HUTCHMED (China)'s ROE % for the quarter that ended in Dec. 2023 was -17.92%. HUTCHMED (China)'s PB Ratio for the quarter that ended in Dec. 2023 was 4.23. HUTCHMED (China)'s ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -4.24%.


HUTCHMED (China) ROE % Adjusted to Book Value Historical Data

The historical data trend for HUTCHMED (China)'s ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HUTCHMED (China) ROE % Adjusted to Book Value Chart

HUTCHMED (China) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.70 -3.38 -4.34 -11.05 3.55

HUTCHMED (China) Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.07 -13.66 -13.73 18.62 -4.24

Competitive Comparison of HUTCHMED (China)'s ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HUTCHMED (China)'s ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where HUTCHMED (China)'s ROE % Adjusted to Book Value falls into.



HUTCHMED (China) ROE % Adjusted to Book Value Calculation

HUTCHMED (China)'s ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=15.03% / 4.23
=3.55%

HUTCHMED (China)'s ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-17.92% / 4.23
=-4.24%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HUTCHMED (China) ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of HUTCHMED (China)'s ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


HUTCHMED (China) (HUTCHMED (China)) Business Description

Traded in Other Exchanges
Address
2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.